Literature DB >> 20421276

Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells.

Jeroen J W M Janssen, Fedor Denkers, Peter Valk, Jan J Cornelissen, Gerrit-Jan Schuurhuis, Gert J Ossenkoppele.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20421276      PMCID： PMC2878808          DOI： 10.3324/haematol.2009.015693

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications.

Authors:  T T Nguyen; A F Mohrbacher; Y C Tsai; J Groffen; N Heisterkamp; P W Nichols; M C Yu; M Lübbert; P A Jones
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

2.  Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia.

Authors:  S Mizuno ; T Chijiwa; T Okamura; K Akashi; Y Fukumaki; Y Niho; H Sasaki
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

3.  Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.

Authors:  C Nguyen; G Liang; T T Nguyen; D Tsao-Wei; S Groshen; M Lübbert; J H Zhou; W F Benedict; P A Jones
Journal:  J Natl Cancer Inst       Date:  2001-10-03       Impact factor: 13.506

4.  Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

Authors:  Yasuhiro Oki; Hagop M Kantarjian; Vazganush Gharibyan; Dan Jones; Susan O'brien; Srdan Verstovsek; Jorge Cortes; Gail M Morris; Guillermo Garcia-Manero; Jean-Pierre J Issa
Journal:  Cancer       Date:  2007-03-01       Impact factor: 6.860

5.  Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.

Authors:  Eric Deutsch; Sylvie Jarrousse; Dorothee Buet; Aymeric Dugray; Marie-Laure Bonnet; Marie-Catherine Vozenin-Brotons; Francois Guilhot; Ali G Turhan; Jean Feunteun; Jean Bourhis
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

6.  The estrogen receptor CpG island is methylated in most hematopoietic neoplasms.

Authors:  J P Issa; B A Zehnbauer; C I Civin; M I Collector; S J Sharkis; N E Davidson; S H Kaufmann; S B Baylin
Journal:  Cancer Res       Date:  1996-03-01       Impact factor: 12.701

7.  Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.

Authors:  Hagop M Kantarjian; Susan O'Brien; Jorge Cortes; Francis J Giles; Stefan Faderl; Jean-Pierre Issa; Guillermo Garcia-Manero; Mary Beth Rios; Jianqin Shan; Michael Andreeff; Michael Keating; Moshe Talpaz
Journal:  Cancer       Date:  2003-08-01       Impact factor: 6.860

8.  Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa.

Authors:  Jose Roman-Gomez; Juan A Castillejo; Antonio Jimenez; Francisco Cervantes; Concepcion Boque; Lourdes Hermosin; Angel Leon; Albert Grañena; Dolors Colomer; Anabel Heiniger; Antonio Torres
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

9.  Methylation of tumour suppressor gene promoters in the presence and absence of transcriptional silencing in high hyperdiploid acute lymphoblastic leukaemia.

Authors:  Kajsa Paulsson; Qian An; Anthony V Moorman; Helen Parker; Gael Molloy; Teresa Davies; Mike Griffiths; Fiona M Ross; Julie Irving; Christine J Harrison; Bryan D Young; Jon C Strefford
Journal:  Br J Haematol       Date:  2008-12-19       Impact factor: 6.998

10.  Sequential gene promoter methylation during HPV-induced cervical carcinogenesis.

Authors:  F E Henken; S M Wilting; R M Overmeer; J G I van Rietschoten; A O H Nygren; A Errami; J P Schouten; C J L M Meijer; P J F Snijders; R D M Steenbergen
Journal:  Br J Cancer       Date:  2007-10-30       Impact factor: 7.640
View more
  4 in total

1.  BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia.

Authors:  Elisa Leo; Manuela Mancini; Michela Aluigi; Simona Luatti; Fausto Castagnetti; Nicoletta Testoni; Simona Soverini; Maria Alessandra Santucci; Giovanni Martinelli
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

2.  DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15- cells in early chronic-phase chronic myeloid leukemia.

Authors:  Stéphanie Maupetit-Mehouas; Franck Court; Céline Bourgne; Agnès Guerci-Bresler; Pascale Cony-Makhoul; Hyacinthe Johnson; Gabriel Etienne; Philippe Rousselot; Denis Guyotat; Alexandre Janel; Eric Hermet; Sandrine Saugues; Juliette Berger; Philippe Arnaud; Marc G Berger
Journal:  Mol Oncol       Date:  2018-04-27       Impact factor: 6.603

3.  Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.

Authors:  G Heller; T Topakian; C Altenberger; S Cerny-Reiterer; S Herndlhofer; B Ziegler; P Datlinger; K Byrgazov; C Bock; C Mannhalter; G Hörmann; W R Sperr; T Lion; C C Zielinski; P Valent; S Zöchbauer-Müller
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528

Review 4.  Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.

Authors:  Fabien Muselli; Jean-François Peyron; Didier Mary
Journal:  Int J Mol Sci       Date:  2019-11-10       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.